Login to Your Account



Gilead, Pharmacyclics to Benefit?

Higher Death Rate Prompts Halt in Revlimid CLL Trial

By Jennifer Boggs
Managing Editor

Friday, July 19, 2013
Analysts remained relatively unconcerned following Celgene Corp.'s news that it halted a Phase III study testing Revlimid (lenalidomide) in front-line elderly B-cell chronic lymphocytic leukemia (CLL) due to an imbalance in the number of deaths between the Revlimid and control arms, though up and coming competitors could benefit from the minor setback.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription